Medical Oncology

Doç. Dr. Şafak Yıldırım Dişli

Doctor and researcher Acıbadem Kayseri Hastanesi Kayseri
Breast Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: acibadem.com.tr.

  • Akciğer, Akciğer Zarı Kanserleri (Mezotelyoma) ve Diğer Torasik Kanserler
  • Baş Boyun Kanserleri
  • Meme Kanseri
  • Mesane Kanseri
  • Mide Kanseri
  • Özofagus Kanseri
  • Pankreas Kanseri
  • Prostat Kanseri
  • Jinekolojik Tümörler ve Kanserler (Rahim, Serviks, Yumurtalık/Over Kanseri vb.)
  • Kolorektal Kanserler (Kolon ve Rektum Kanseri)
  • Akciğer Kanseri
  • Kolon (Kalın Bağırsak) Kanseri

CV

Education and experience

From source

Experience

  • 2024Acıbadem Sağlık Grubuacibadem.com.tr

Education

  • 2022Karadeniz Teknik Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji, Üst Uzmanlıkacibadem.com.tr
  • 2018Recep Tayyip Erdoğan Üniversitesi Rize Eğitim ve Araştırma Hastanesi, İç Hastalıkları, Uzmanlıkacibadem.com.tr
  • 2012Atatürk Üniversitesi Tıp Fakültesi, Üniversiteacibadem.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologyacibadem.com.trFrom source
  • InstitutionAcıbadem Kayseri Hastanesiacibadem.com.trFrom source
  • Area of workBreast NeoplasmsExtracted from 3 publications · Model version —From source
  • Publications28 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-5869-0679ORCIDFrom source
  • Last synchronised4 November 2026 20:48https://www.acibadem.com.tr/doktor/safak-yildirim-disli/acibadem.com.tr

Scientific work

Publications on Breast Neoplasms

28 publications
Publications by year Most: 9, in 2024
  1. 2015: 1 publication
  2. 2016: 2 publications
  3. 2017: 1 publication
  4. 2018: 0 publications
  5. 2019: 1 publication
  6. 2020: 1 publication
  7. 2021: 0 publications
  8. 2022: 4 publications
  9. 2023: 1 publication
  10. 2024: 9 publications
  11. 2025: 4 publications
  12. 2026: 4 publications

  1. Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

    Discover Oncology, 2026

    DOI 10.1007/s12672-026-04842-3 PMID 41870760 Open-access full textSource: OpenAlex

  2. Demographic Characteristics, Clinical Features, and Treatment Patterns of Classic and AIDS-Related Kaposi Sarcoma: A Multicenter Real-World Study from Turkey

    Medicina, 2026

    DOI 10.3390/medicina62081483 PMID 42654381 Open-access full textSource: ORCID

  3. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-44980-w PMID 41888201 Open-access full textSource: OpenAlex

  4. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor–positive, HER-2–negative metastatic breast cancer: A real-world, multicenter, retrospective study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e24144 Source: OpenAlex

  5. Efficacy of anti-VEGF & anti-EGFRs in microsatellite instable (MSI-H) metastatic colorectal cancer, Turkish Oncology Group (TOG) study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e15507 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  6. Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study

    Current Oncology, 2025

    DOI 10.3390/curroncol32110639 PMID 41294701 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  7. Second Line Therapies After Tyrosine Kinase Inhibitory in Metastatic Renal Cell Carcinoma

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2024.107988 Open-access full textSource: OpenAlex

  8. AGE-RELATED OUTCOMES IN ELDERLY PATIENTS RECEIVING CDK4/6 INHIBITORS FOR HR+/HER2- METASTATIC BREAST CANCER: A RETROSPECTIVE MULTICENTER STUDY

    The Breast, 2025

    DOI 10.1016/s0960-9776(25)00723-4 Open-access full textSource: OpenAlex

  9. Assessment of tumor location in adjuvant treatment decision for stage II colon cancer

    Anatolian Current Medical Journal, 2024

    DOI 10.38053/acmj.1482701 Open-access full textSource: ORCID

  10. The Effect of Metformin on Survival in Patients with Non-Small Cell Lung Cancer

    Sağlık Bilimlerinde Değer, 2024

    DOI 10.33631/sabd.1216847 Open-access full textSource: ORCID

View all 28 publications